gtglabs.com (GENE) - יתרות מזומנים בחישוב למניה

The development of Genetic Technologies (GENE) is constrained by liquidity and a dependence on insurance payouts. Revenue is generated through the sale of early detection tests for breast cancer and cardiopathologies, as reflected in the GURU.Markets cash per share chart, where the 0.08 level captures the current state. Genetic Technologies (GENE) earns from the predictive diagnostics of chronic diseases by assessing patients' genetic risks.
פילוחי מדדים מקיפים ואנליטיקה עבור Genetic Technologies Ltd (GENE)

This indicator determines the volume of liquid assets per ordinary share. The calculation captures the company's actual cash cushion, excluding market capitalization overvaluation. The trend of cash reserves per share in the GURU.Markets system demonstrates the issuer's ability to sustain operational activities. For Genetic Technologies (GENE), this resource is critical when scaling geneType IT tests. Sufficient capital ensures the expansion of b2b services within the oncology diagnostics segment.